Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stuart Glasser

Procedural Dermatology Greensburg, PA Medical Doctor

NPI 1821042862 CMS profile 263847

916 Green St, Greensburg, PA 15601

Open in the dashboard

General payments

$13,309

751 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stuart Glasser of Greensburg, PA is reported in the CMS Open Payments database as having received $13,309 across 751 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,801 93
2024 General $1,974 119
2023 General $2,094 123
2022 General $2,337 131
2021 General $1,607 92
2020 General $1,617 81
2019 General $1,879 112

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stuart Glasser
  • Procedural Dermatology median
  • Middle half of Procedural Dermatology
  • National median

In program year 2025, general payments to Stuart Glasser were reported at $1,801. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.

Show as a table
Year Stuart Glasser Procedural Dermatology median Middle half National median
2019 $1,879 $454 $152–$1,260 $163
2020 $1,617 $243 $90–$835 $114
2021 $1,607 $337 $102–$1,128 $132
2022 $2,337 $443 $119–$1,654 $149
2023 $2,094 $583 $137–$1,838 $160
2024 $1,974 $611 $132–$1,835 $164
2025 $1,801 $592 $144–$1,778 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,043 173 payments
  2. Janssen Biotech, Inc. $1,689 142 payments
  3. Amgen Inc. $1,259 46 payments
  4. Novartis Pharmaceuticals Corporation $1,082 61 payments
  5. Pfizer Inc. $634 39 payments
  6. E.R. Squibb & Sons, L.L.C. $613 52 payments
  7. Sun Pharmaceutical Industries Inc. $542 22 payments
  8. Genzyme Corporation $463 18 payments
  9. UCB, Inc. $461 19 payments
  10. Merz North America, Inc. $369 6 payments
  11. Other $3,155 173 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,128 745 payments
  2. Education $180 6 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI $1,618 81 payments
  2. Otezla $1,154 40 payments
  3. TREMFYA $1,130 88 payments
  4. RINVOQ $707 57 payments
  5. SIMPONI ARIA $618 64 payments
  6. STELARA $618 64 payments
  7. SIMPONI $618 64 payments
  8. SOTYKTU $549 50 payments
  9. REMICADE $487 50 payments
  10. DUPIXENT $455 17 payments
  11. Other $7,121 379 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

842

Median for Dermatology: 534

Drug cost

$16,699

Median for Dermatology: $67,151

Branded share of claims

9.4%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 125 $4,451
Dapsone Generic 19 $1,582
Tretinoin Generic 14 $1,514
Fluorouracil Generic 19 $1,341
Econazole Nitrate Generic 28 $1,126
Triamcinolone Acetonide Generic 118 $885
Betamethasone Dipropionate Generic 27 $701
Methotrexate Methotrexate Sodium Brand 19 $687
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 36 $648
Metronidazole Generic 13 $610

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$93,009

Of which drugs: $16

Medicare patients

552

Average age 74

Services billed

1,683

279 women, 273 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 47%
Ischemic heart disease 24%
Diabetes 22%
Chronic kidney disease 16%
Cancer 15%
Atrial fibrillation 13%
Osteoporosis 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 28 $16

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $230
$230 — —
Otezla
  • Amgen Inc. $200
$200 — —
DUPIXENT
  • GENZYME CORPORATION $149
  • Regeneron Healthcare Solutions, Inc. $42
$191 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $163
$163 — —
TREMFYA
  • Janssen Biotech, Inc. $160
$160 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

751 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Procedural Dermatology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record